Articles related to BUSINESS & POLICY

The FDA’s 2024 agenda navigates the complexities of AI, cybersecurity, and emergency use authorizations, setting the stage for a transformative era in medtech.

The ACA’s preventive care mandate, currently under constitutional review, has significantly impacted rates of cancer screenings and early-stage diagnoses. The outcome of this case could reshape the landscape of preventive care in oncology.

The study’s findings suggest that industry payments to oncologists could potentially influence treatment decisions, leading to the prescription of nonrecommended or low-value treatments. This raises important questions about the potential impacts of these payments on patient care.

The “revolving door” phenomenon, exemplified by the transition of Doran Fink from the FDA to Moderna, raises critical questions about public trust and regulatory integrity. As healthcare professionals, understanding these dynamics can inform our perspectives on regulatory processes and pharmaceutical industry relationships.

The study underscores the potential influence of pharmaceutical industry payments on the delivery of non-recommended or low value interventions in cancer treatment. It highlights the need for increased transparency and scrutiny in the financial relationships between physicians and the industry.

The recent suspension of Dr. Benjamin Neel, former director of NYU’s Perlmutter Cancer Center, underscores the importance of academic integrity in the medical field. As healthcare professionals, it’s crucial to uphold the highest standards of conduct in our research.